Savaria Announces 2017 First Quarter Results Release Date

LAVAL, QUEBEC -- (Marketwired) -- 04/27/17 -- Savaria Corporation ("Savaria") (TSX: SIS), one of North America's leaders in the accessibility industry, will release its 2017 first quarter results after market hours on May 11th, 2017.

Savaria Corporation (savaria.com) is one of North America's leaders in the accessibility industry. It provides accessibility solutions for the elderly and physically challenged to increase their mobility and independence. The diversity of its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts, as well as elevators for home and commercial use. In addition, it converts and adapts vehicles to be wheelchair accessible. It also operates a network of franchisees and corporate stores through which new and recycled accessibility equipment is sold, as well as vehicle conversion in certain locations. Savaria operates a plant located in Huizhou (China), which increases its competitive edge. The Corporation records more than 60% of its revenue outside Canada, primarily in the United States. It operates a sales network of some 400 retailers and affiliates in North America and employs some 500 people. Its principal places of business are located in Laval (Quebec), Brampton (Ontario) and Huizhou (China).

Facebook: https://www.facebook.com/savariabettermobility

Twitter: https://twitter.com/Mobilityforlife

Contacts:
Helene Bernier, CPA, CA
Vice-President, Finance
1-800-931-5655, ext. 248
[email protected]

Marcel Bourassa
President and Chief Executive Officer
1-800-661-5112
[email protected]
www.savaria.com

Source: Savaria Corporation

You May Also Be Interested In

• Entera Bio names Riccardo Camisasca as chief medical officer
• SAINT JOSEPH'S UNIVERSITY ANNOUNCES THE INITIATIVE FOR HUMAN FORMATION IN AN AGE OF AI
• Andelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen's University to Treat GM2 Gangliosidoses